<DOC>
	<DOCNO>NCT00196820</DOCNO>
	<brief_summary>Study do patient metastatic breast cancer order determine efficacy capecitabine</brief_summary>
	<brief_title>Mono Efficacy Capecitabine ( MoniCa )</brief_title>
	<detailed_description>Study design : Prospective , open phase II trial Treatment : Capecitabine 2000 mg/m² orally day 1-14 q day 22 progression , unacceptable toxicity , patient 's request withdrawal study Primary objective To determine time disease progression patient HER2 negative metastatic breast cancer 1st line monochemotherapy capecitabine Secondary objectives 1 . To determine objective response rate 2 . To determine duration response 3 . To determine clinical benefit define CR , PR , stable disease ≥ 24 week 4 . To evaluate safety toxicity capecitabine 5 . To assess quality life within 1 year start capecitabine treatment 6 . To determine overall survival 7 . To determine objective response rate male patient 8 . To evaluate QoL modify Brunner Score ( Appendix 7 ) Tertiary objective To determine DPD Proteomics serum</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Written inform consent prior begin specific protocol procedure , include expect cooperation patient treatment followup , must obtain document accord local regulatory requirement . 2 . Histologically confirm carcinoma breast . 3 . Negative HER2overexpression primary and/or metastatic tumour tissue detect immunohistochemistry ( DAKO 02 ) genamplification detect FISH . 4 . Locally advanced metastatic stage disease suitable surgery radiotherapy alone . 5 . The follow previous systemic treatment eligible : adjuvant chemotherapy ( except capecitabine include ) adjuvant endocrine therapy palliative endocrine treatment treatment bisphosphonates ( adjuvant and/or palliative ) treatment immunotherapy ( adjuvant and/or palliative ) 6 . Patients must either measurable nonmeasurable target lesion accord WHO criterion ( see Appendix 5 ) . 7 . At least 4 week since radiotherapy , full recovery . The measurable disease must completely outside radiation portal must pathologic proof progressive disease . 8 . Complete radiology tumor measurement work within 4 week prior registration . 9 . Karnofsky performance status evaluation &gt; = 60 % 10 . Age &gt; 18 year 11 . WBC &gt; = 3000 cells/microl , platelet count &gt; = 100,000 cells/microl . 12 . Bilirubin &lt; = 2x upper limit normal institution ( ULN ) ; elevation transaminases alkaline phosphatase &lt; 2.5x ULN &lt; 5x ULN patient liver metastasis . 13 . Creatinine &lt; = 1,25 x upper normal value creatininclearance &gt; 50 ml/min ( accord Cockroft Gault ) . 14 . If childbearing potential , negative pregnancy test . In addition patient agree use effective method avoid pregnancy duration study . 15 . Female male patient 1 . Known hypersensitivity reaction compound incorporated substance know dihydropyrimidine dehydrogenase deficiency . 2 . Concurrent immunotherapy hormonal therapy ( antihormonal , contraceptive and/or replacement therapy ) . Bisphosphonates may continue . 3 . Parenchymal brain metastasis , unless adequately control surgery and/or radiotherapy complete resolution symptom discontinuation steroid . 4 . Life expectancy le 3 month . 5 . Serious intercurrent medical psychiatric illness may interfere plan treatment ( include AIDS serious active infection ) . 6 . History malignancy within last 5 year could affect diagnosis assessment metastatic breast cancer . 7 . Patients indication polychemotherapy . 8 . Concurrent treatment experimental drug . Participation another clinical trial investigational market drug within 30 day prior study entry . 9 . Treatment sorivudine derivates e.g . brivudin . 10 . Pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>HER2 negative , medium-risk , metastatic breast cancer</keyword>
</DOC>